Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rotigaptide SCHEMBL20547994 | 1.00 | VHL (0.49) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| Rotigaptide SCHEMBL20547993 | 1.00 | VHL (0.49) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| SCHEMBL19381802 | 0.94 | VHL (0.47) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL16925996 | 0.94 | VHL (0.47) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL20626228 | 0.93 | VHL (0.52) | VHLOPRD1OPRM1BDKRB2NMUR2 | |
| SCHEMBL31327461 | 0.86 | VHL (0.54) | VHLOPRD1OPRM1BDKRB2 | |
| SCHEMBL20782464 | 0.80 | F2 (0.37) | VHLOPRD1OPRM1 | |
| SCHEMBL10624291 | 0.79 | VHL (0.42) | VHLOPRD1BDKRB2 | |
| SCHEMBL19381804 | 0.78 | VHL (0.51) | VHLOPRD1OPRM1 | |
| SCHEMBL16925966 | 0.77 | VHL (0.52) | VHLOPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324799-B2 | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease | ZEALAND PHARMA A/S (DK) | 2022-05-10 | — | — | US | claimed |
| EP-4739309-A1 | DANEGAPTIDE FOR USE IN TREATING SYNUCLEINOPATHIES | Cambridge Enterprise Limited (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739352-A1 | HUMAN THERAPY UTILIZING NOVEL PROKARYOTIC VOLTAGE GATED SODIUM CHANNELS | Duke University (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| US-20260077104-A1 | Bioelectric Thread and Delivery Device | UNIV BROWN (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709357-A2 | EXTRACELLULAR VESICLE COMPOSITIONS AND PREPARATION | Virginia Tech Intellectual Properties, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3958886-A1 | COMPOSITIONS AND METHODS FOR PROTECTING EPITHELIAL AND BARRIER INTEGRITY | Ocunexus Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114025786-A | Compositions and methods for protecting epithelial and barrier integrity | 欧耐柯萨斯医疗有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | VHL 2374/4885OPRD1 3942/4885OPRM1 3404/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | VHL 1994/4885OPRD1 905/4885OPRM1 1215/4885 |
| US-20260077104-A1 | Bioelectric Thread and Delivery Device | TNNI3, TNNT2, TTN | VHL 4523/4885OPRD1 3953/4885OPRM1 4673/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | VHL 2336/4885OPRD1 2834/4885OPRM1 1506/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | VHL 1475/4885OPRD1 3734/4885OPRM1 3000/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | VHL 2776/4885OPRD1 2236/4885OPRM1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.